Эффективность Гептрала® в лечении печеночной токсичности, обусловленной цитостатической химиотерапией


Снеговой А.В., Манзюк Л.В.

Российский онкологический научный центр им. Н.Н. Блохина РАМН, Москва
У 19 пациентов с различными злокачественными опухолями проведена оценка эффективности препарата Гептрал® (адеметионин) при лечении гепатотоксичности, индуцированной химиотерапией. Показано, что при 4-недельном приеме Гептрала® внутрь по 400 мг 2 раза в день уровень трансаминаз снизился до нормы у 10 из 12 пациентов с 1-й степенью гепатотоксичности. Для нормализации уровня трансаминаз при 2-й степени гепатотоксичности потребовался более длительный прием Гептрала® (от 2 до 4 месяцев). Режим химиотерапии в период применения Гептрала® не менялся.

Литература


1. King PD, Perry MC. Hepatoioxiciry of chemotherapy. The Oncologist 2001; 6:162–76.


2. DeLeve LD, Kaplovitz N. Mechanisms of druginduced liver disease. Gastroenterol Clin North Am 1995;24:787–810.


3. Dansette PM, Bonierbale E, Minoletti С, et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23:443–51.


4. Kaplowitz N, Aw TY, Simon FR et al. Druginduced hepatotoxicity. Ann Intern Med 1986;104:826–39.


5. Ishak KG, Zimmerman HJ. Morphologic spectrums of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:759–86.


6. Larrey D. Drug-induced liver diseases. J Hepatol 2000;32:77–88.


7. Zorti D, et al. Chemotherapy–associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surgery 2007;94:274–86.


8. Paul D, et al. Hepatotoxicity of chemotherapy. The Oncologist 2001;6:162–76.


9. O’ Grady JG. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997;26:41–46.


10. Strieker BH. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier, 1992.


11. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford University Press 1999;2:1261–315.


12. Hirata F, Viveros OH, Diliberto EJ. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci USA 1978;75:1718–21.


13. Kretzschmar M, Klinger W. The hepatic glutathione system influences of xenobiotics. Exp Pathol 1990;38:145–64.


14. Cabrero C, Duce AM, Ortiz P, et al. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 1988;8:1530–34.


15. Cantoni GL. The nature of the active methyl donor formed enzymically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74:2942–43.


16. Dunne JB, Davenport M, Williams R, et al. Evidence that S-adenosylmethionine and N-acetylcysteine reduce injury from sequential cold and warm ischaemia in the isolated perfused rat liver. Transplantation 1994;57:1161–68.


17. Mato JM, Camara J, Fernandez de Paz J, et al. Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081–89.


18. Giudici GA, Le Grazie С, Di Padova C. The use of ademethionine (SAMe) in the treatment of cholestatic liver disorders: meta-analvsis of clinical trials. Methionine Metabolism: Molecular Mechanism and Clinical Implications. Madrid: CSIC Press pp 1992;67–9.


19. Feliu J, Mel JR, Camps C, et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. An active and low toxicity regimen. Eur J Cancer 2002; З8:1204–11.


20. Cascinu S, Graziano F, Ferrau F, et al. Raltitrexed plus oxaliplatin (TOMOX) as firstline chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002; 13:716–20.


Похожие статьи


Бионика Медиа